Zacks Research Reduces Earnings Estimates for HealthEquity

HealthEquity, Inc. (NASDAQ:HQY - Free Report) - Equities researchers at Zacks Research cut their Q3 2027 earnings per share (EPS) estimates for shares of HealthEquity in a report issued on Tuesday, June 24th. Zacks Research analyst R. Department now expects that the company will earn $0.88 per share for the quarter, down from their prior forecast of $0.91. The consensus estimate for HealthEquity's current full-year earnings is $2.32 per share.

HealthEquity (NASDAQ:HQY - Get Free Report) last announced its earnings results on Tuesday, June 3rd. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.81 by $0.16. HealthEquity had a return on equity of 11.01% and a net margin of 9.80%. The company had revenue of $330.80 million for the quarter, compared to analyst estimates of $322.25 million. During the same period in the prior year, the company posted $0.80 EPS.

A number of other equities research analysts also recently weighed in on HQY. Barrington Research boosted their price target on HealthEquity from $112.00 to $125.00 and gave the company an "outperform" rating in a report on Thursday, June 5th. Royal Bank Of Canada boosted their price target on HealthEquity from $112.00 to $117.00 and gave the company an "outperform" rating in a report on Wednesday, June 4th. Bank of America upped their price objective on HealthEquity from $110.00 to $125.00 and gave the stock a "buy" rating in a research note on Wednesday, June 4th. Deutsche Bank Aktiengesellschaft upped their price objective on HealthEquity from $98.00 to $115.00 and gave the stock a "buy" rating in a research note on Thursday, June 5th. Finally, The Goldman Sachs Group upped their price objective on HealthEquity from $94.00 to $104.00 and gave the stock a "neutral" rating in a research note on Wednesday, June 4th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $118.09.

HealthEquity Price Performance

Shares of NASDAQ HQY opened at $103.97 on Thursday. HealthEquity has a twelve month low of $65.01 and a twelve month high of $116.65. The company has a current ratio of 4.06, a quick ratio of 4.06 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $8.99 billion, a price-to-earnings ratio of 75.89, a price-to-earnings-growth ratio of 1.59 and a beta of 0.49. The business has a 50 day simple moving average of $97.20 and a 200-day simple moving average of $97.90.

Insiders Place Their Bets

In other HealthEquity news, Director Jon Kessler sold 134,183 shares of the business's stock in a transaction on Friday, June 6th. The stock was sold at an average price of $112.08, for a total transaction of $15,039,230.64. Following the completion of the transaction, the director now owns 253,510 shares in the company, valued at approximately $28,413,400.80. The trade was a 34.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Michael Henry Fiore sold 8,881 shares of the company's stock in a transaction on Friday, April 4th. The shares were sold at an average price of $78.26, for a total value of $695,027.06. Following the completion of the sale, the executive vice president now owns 56,655 shares of the company's stock, valued at approximately $4,433,820.30. This trade represents a 13.55% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 304,581 shares of company stock worth $33,664,018. 1.50% of the stock is owned by company insiders.

Institutional Trading of HealthEquity

Several institutional investors have recently modified their holdings of the company. Wealthfront Advisers LLC acquired a new stake in shares of HealthEquity in the fourth quarter valued at $10,304,089,000. Vanguard Group Inc. lifted its holdings in shares of HealthEquity by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 8,976,091 shares of the company's stock valued at $861,256,000 after buying an additional 99,624 shares during the period. FMR LLC lifted its holdings in shares of HealthEquity by 2.4% in the fourth quarter. FMR LLC now owns 5,415,800 shares of the company's stock valued at $519,646,000 after buying an additional 125,684 shares during the period. Invesco Ltd. lifted its holdings in shares of HealthEquity by 50.6% during the first quarter. Invesco Ltd. now owns 2,446,198 shares of the company's stock valued at $216,171,000 after purchasing an additional 821,425 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of HealthEquity by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 2,089,398 shares of the company's stock valued at $200,522,000 after purchasing an additional 10,421 shares during the last quarter. Institutional investors and hedge funds own 99.55% of the company's stock.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.